Andreas Emmenegger
Direktor/Vorstandsmitglied bei LUZERNER KANTONALBANK AG
Aktive Positionen von Andreas Emmenegger
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
LUZERNER KANTONALBANK AG | Direktor/Vorstandsmitglied | 01.01.2016 | - |
Targimmune Therapeutics AG
Targimmune Therapeutics AG Pharmaceuticals: MajorHealth Technology Targimmune Therapeutics AG engages in the drug development using novel targeted onco-immunotherapies. The company was founded by Andreas Emmenegger and Peter Kash and is headquartered in Basel, Switzerland. | Gründer | - | - |
Corporate Officer/Principal | - | - | |
Molecular Partners, Inc.
Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Part of Molecular Partners AG, Molecular Partners, Inc. operates as a clinical-stage biopharmaceutical company. The company is based in Cambridge, MA. The CEO of the company is Patrick Amstutz. | Corporate Officer/Principal | - | - |
Karriereverlauf von Andreas Emmenegger
Ehemalige bekannte Positionen von Andreas Emmenegger
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
MOLECULAR PARTNERS AG | Finanzdirektor/CFO | 01.01.2006 | 31.12.2022 |
PIQUR Therapeutics AG
PIQUR Therapeutics AG Pharmaceuticals: OtherHealth Technology PIQUR Therapeutics AG engages in development of anti-cancer drugs based on the inhibition. Its products include PQR309, PQR620 and PQR5xx. The company was founded by Bernd Giese, Vladimir Cmiljanovic, Andreas Emmenegger, Ralf Rosenow and Matthias Wymann in August 2011 and is headquartered in Basel, Switzerland. | Direktor/Vorstandsmitglied | 01.08.2011 | 01.04.2018 |
Gründer | 01.08.2011 | 01.04.2018 | |
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | 01.01.2006 | 01.01.2007 |
Roche Glycart AG
Roche Glycart AG Pharmaceuticals: MajorHealth Technology Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland. | Finanzdirektor/CFO | 01.02.2005 | 01.01.2006 |
THE FANTASTIC COMPANY AG | Finanzdirektor/CFO | 01.01.2000 | 01.01.2003 |
INTERROLL HOLDING AG | Finanzdirektor/CFO | 01.01.1997 | 01.01.2000 |
░░░░░░░ ░░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
Ausbildung von Andreas Emmenegger
Lucerne University of Applied Sciences & Arts | Undergraduate Degree |
Instituto de Estudios Superiores de la Empresa | Masters Business Admin |
Statistik
International
Schweiz | 12 |
Spanien | 2 |
Vereinigte Staaten | 2 |
Operativ
Director of Finance/CFO | 5 |
Corporate Officer/Principal | 4 |
Undergraduate Degree | 2 |
Sektoral
Health Technology | 8 |
Finance | 3 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 4 |
---|---|
ROCHE HOLDING AG | Health Technology |
LUZERNER KANTONALBANK AG | Finance |
INTERROLL HOLDING AG | Producer Manufacturing |
MOLECULAR PARTNERS AG | Health Technology |
Private Unternehmen | 7 |
---|---|
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Health Technology |
The Fantastic Co. AG
The Fantastic Co. AG Financial ConglomeratesFinance The Fantastic Co. AG operates as a holding company. It engages in purchasing, retaining and administering shareholdings in other companies. The firm offers accessories and fashion products through their retail partners. The company was founded on November 15, 1996 and is headquartered in Zug, Switzerland. | Finance |
Roche Glycart AG
Roche Glycart AG Pharmaceuticals: MajorHealth Technology Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland. | Health Technology |
Dräger Beteiligungen AG | |
PIQUR Therapeutics AG
PIQUR Therapeutics AG Pharmaceuticals: OtherHealth Technology PIQUR Therapeutics AG engages in development of anti-cancer drugs based on the inhibition. Its products include PQR309, PQR620 and PQR5xx. The company was founded by Bernd Giese, Vladimir Cmiljanovic, Andreas Emmenegger, Ralf Rosenow and Matthias Wymann in August 2011 and is headquartered in Basel, Switzerland. | Health Technology |
Targimmune Therapeutics AG
Targimmune Therapeutics AG Pharmaceuticals: MajorHealth Technology Targimmune Therapeutics AG engages in the drug development using novel targeted onco-immunotherapies. The company was founded by Andreas Emmenegger and Peter Kash and is headquartered in Basel, Switzerland. | Health Technology |
Molecular Partners, Inc.
Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Part of Molecular Partners AG, Molecular Partners, Inc. operates as a clinical-stage biopharmaceutical company. The company is based in Cambridge, MA. The CEO of the company is Patrick Amstutz. | Health Technology |
- Börse
- Insiders
- Andreas Emmenegger
- Erfahrung